These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22966947)

  • 1. Quality-adjusted life years in cancer: pros, cons, and alternatives.
    Woodward RM; Menzin J; Neumann PJ
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):12-9. PubMed ID: 22966947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
    Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
    Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic evaluation of targeted cancer therapy].
    Ikeda S
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):967-70. PubMed ID: 23986036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methods of comparative economic evaluations of therapies and for rational allocation of resources across sectors of health care systems - introduction, advantages, risks].
    Wasem J; Hessel F; Kerim-Sade C
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S12-20. PubMed ID: 11533902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Philosophical concerns regarding cost-effectiveness analyses.
    Weiner BK
    Med Hypotheses; 2010 Feb; 74(2):383-6. PubMed ID: 19651478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of quality-adjusted life-years in cost-effectiveness studies.
    Sculpher M
    Allergy; 2006 May; 61(5):527-30. PubMed ID: 16629779
    [No Abstract]   [Full Text] [Related]  

  • 8. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?
    Greenberg D; Neumann PJ
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):113-9. PubMed ID: 21351863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Methodology of economic assessment: example in oncology].
    Jaisson-Hot I; Schott AM; Clippe C; Ganne C; Hajri T; Poncet B; Trillet-Lenoir V; Colin C
    Bull Cancer; 2003 Nov; 90(11):939-45. PubMed ID: 14706896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
    Pickard AS; Wang Z; Walton SM; Lee TA
    Health Qual Life Outcomes; 2005 Mar; 3():11. PubMed ID: 15748287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life: questionnaires and questions.
    Mooney A
    J Health Commun; 2006; 11(3):327-41. PubMed ID: 16624797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward a broader view of values in cost-effectiveness analysis of health.
    Menzel P; Gold MR; Nord E; Pinto-Prades JL; Richardson J; Ubel P
    Hastings Cent Rep; 1999; 29(3):7-15. PubMed ID: 10420299
    [No Abstract]   [Full Text] [Related]  

  • 15. Ethical and value issues in insurance coverage for cancer treatment.
    Brock DW
    Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of multilevel hemilaminectomy for lumbar stenosis-associated radiculopathy.
    Parker SL; Fulchiero EC; Davis BJ; Adogwa O; Aaronson OS; Cheng JS; Devin CJ; McGirt MJ
    Spine J; 2011 Aug; 11(8):705-11. PubMed ID: 21641874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring costs: administrative claims data, clinical trials, and beyond.
    Etzioni R; Riley GF; Ramsey SD; Brown M
    Med Care; 2002 Jun; 40(6 Suppl):III63-72. PubMed ID: 12064760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can comparative effectiveness research help reduce health care costs?
    Natl Bur Econ Res Bull Aging Health; 2011; (3):3-4. PubMed ID: 22207918
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.